Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

NCT02547922 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02547922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02547922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2015
Completion date
January 18, 2021
Enrollment
147 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis